Company intelligence / Profile preview

Zenflow

South San Francisco, California, United Stateszenflow.com ↗

Ownership: Private
Development stage: NDA

Overview

Zenflow’s Spring System is a minimally invasive, reversible implant designed to relieve urinary symptoms caused by benign prostatic hyperplasia. Three-year data from pilot studies show a 46% improvement in International Prostate Symptom Score, sustained symptom relief, improved quality of life, and no deterioration in sexual function. The pivotal BREEZE™ study is ongoing in the US and Canada

Therapeutic areas: Men's Health
Modalities: DeviceMedical device (implantable spring-like coil)
Industry: Implantable Medical Devices

Drug pipeline

1 asset

Spring System

NDA

Indications: Benign prostatic hyperplasia (BPH)

Partnerships

Cook Medical (strategic investor and partner)

Beyond the preview

Go deeper on Zenflow.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Zenflow.

Explore the full profile